10-Q: cbdMD, Inc. Reports Q1 2024 Results: Revenue Declines Amidst Strategic Shifts

cbdMD, Inc. reported a decrease in net sales for the first quarter of fiscal year 2024, alongside a reduction in operating expenses as the company focuses on profitability and strategic initiatives.

Summary

• cbdMD, Inc. reported a net sales decrease of $0.7 million, or 12%, for the three months ended December 31, 2023, compared to the same period in 2022, with total net sales reaching $5.4 million.
• E-commerce sales decreased by $0.5 million, while wholesale sales saw a decrease of $0.2 million.
• The company's cost of sales decreased to 33.8% of net sales, compared to 41.4% in the same period of the previous year.
• Operating expenses decreased by $3.0 million, or 39.3%, year-over-year, primarily due to cost-cutting measures.
• The company experienced a net loss of $1.997 million attributable to common shareholders, compared to a net loss of $4.956 million in the prior year.
• The company's cash and cash equivalents decreased to $1.5 million at December 31, 2023, from $1.8 million at September 30, 2023.
• The company's working capital decreased to $1.4 million at December 31, 2023, from $3.4 million at September 30, 2023.
• The company has a going concern warning due to its working capital position and ability to raise additional funding.
• The company issued convertible promissory notes for $1.25 million in gross proceeds subsequent to the quarter end.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in reducing costs and improving its net loss, the decline in revenue and the going concern warning raise significant concerns. The company is taking steps to diversify its revenue streams, but the overall sentiment is cautious due to the financial challenges.

Positives

• The company significantly reduced its operating expenses by 39.3% year-over-year.
• Cost of sales as a percentage of net sales improved to 33.8% from 41.4% year-over-year.
• The net loss attributable to common shareholders improved by $2.959 million year-over-year.
• The company launched new product lines, including functional mushrooms and hemp-derived products.
• The company expanded its retail presence by launching products in Sprouts Supermarkets.

Negatives

• Net sales decreased by 12% year-over-year.
• E-commerce and wholesale sales both experienced declines.
• The company's cash and cash equivalents decreased to $1.5 million.
• The company's working capital decreased to $1.4 million.
• The company has a going concern warning due to its working capital position and ability to raise additional funding.

Risks

• The company's ability to continue as a going concern is dependent on improving profitability and securing additional funding.
• The company's working capital may not be sufficient to support daily operations for the next twelve months.
• The company faces challenges in the CBD market due to regulatory uncertainty and channel hurdles.
• The company's revenue is declining, and it needs to find ways to increase sales.
• The company's current capital structure is impacting its market capitalization.

Future Outlook

The company is focused on delivering positive earnings through product portfolio optimization, cost structure adjustments, and targeted marketing investments. They are also expanding into new product categories and sales channels to mitigate regulatory hurdles in the CBD market. The company is seeking shareholder approval to simplify its capital structure.

Management Comments

• Management continues to be very focused on delivering positive earnings through a combination of optimizing our product portfolio, right-sizing our cost structure and investing in marketing that will provide positive return on customer acquisition.
• We believe the combined market capitalization of both our common and Series A Preferred is being impacted due to our current capital structure.
• Our goal is to simplify our capital structure and we believe it will help unlock additional equity value and open up more strategic activity for the Company.
• We continue to believe in the long term benefits of hemp-derived cannabinoids, but see a longer-term horizon for federal regulatory clarity.
• At our core, we believe in natural health and wellness solutions and we believe in the benefits derived from functional mushrooms in addition to hemp.

Industry Context

The company is operating in a challenging CBD market with regulatory uncertainty and channel hurdles. The company is expanding into new product categories, such as functional mushrooms, to diversify its revenue streams and mitigate risks associated with the CBD market. The company is also focusing on international expansion and strategic partnerships to grow its business.

Comparison to Industry Standards

• The company's revenue decline is consistent with the broader contraction trends in the CBD wholesale market, which is facing challenges from low-dose, high-priced products.
• The company's focus on cost reduction and operational efficiency aligns with industry trends as companies seek to improve profitability in a competitive market.
• The company's expansion into new product categories, such as functional mushrooms, is a strategy employed by other companies in the health and wellness sector to diversify revenue streams.
• The company's international expansion efforts are similar to other companies in the CBD industry seeking to capitalize on global market opportunities.
• The company's focus on direct-to-consumer sales through its e-commerce platform is a common strategy in the industry, but the company is facing challenges in customer acquisition.

Stakeholder Impact

• Shareholders may be concerned about the company's declining revenue and going concern warning.
• Employees may be affected by the company's cost-cutting measures.
• Customers may benefit from the company's new product offerings.
• Suppliers may be impacted by the company's financial challenges.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to focus on optimizing its product portfolio and cost structure.
• The company will continue to invest in marketing to improve customer acquisition.
• The company will continue to expand into new product categories and sales channels.
• The company will seek shareholder approval to simplify its capital structure.
• The company will continue to explore strategic partnerships and international expansion opportunities.

Key Dates

Keywords

CBD, cannabidiol, hemp, e-commerce, wholesale, net sales, operating expenses, profitability, functional mushrooms, ATRx, hempMD, Paw CBD, cost of sales, working capital, going concern